Marcus Boehm is Director at Vyant Bio, Inc. (VYNT). They have made 1 open-market trade across 1 company since 2021, most recently 2022-04-18.
CIK 0001850698
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $96K since 2021, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VYNT | 56,484 | $38K |
Shares reported on the most recent Form 4, priced at the 2022-04-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VYNT | BUY | 2021-12-06 | 2021-12-07 | $1.69 | $8K | -9.4% | -27.1% | -39.2% |
| VYNT | BUY | 2021-10-27 | 2021-10-28 | $2.10 | $11K | +21.4% | -10.9% | -49.5% |
| VYNT | BUY | 2021-09-29 | 2021-09-30 | $2.44 | $12K | -3.4% | +7.6% | -44.3% |
| VYNT | BUY | 2021-08-25 | 2021-08-26 | $2.58 | $13K | -4.1% | -12.7% | -23.5% |
| VYNT | BUY | 2021-07-28 | 2021-07-28 | $2.92 | $15K | -8.0% | -9.7% | -28.8% |
| VYNT | BUY | 2021-06-30 | 2021-07-01 | $3.76 | $19K | -15.5% | -26.1% | -39.8% |
| VYNT | BUY | 2021-05-28 | 2021-06-01 | $3.68 | $18K | -7.6% | -8.1% | -35.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.